MITOMYCIN C is an antibiotic derived from the fermentation filtrate of Streptomyces caespitosus, a species of Streptomyces isolated from a soil sample collected in Tokyo in 1955.1 It has a broad spectrum of activity against gram positive and gram negative bacteria, rickettsiae, and certain viruses as well as a high degree of chemotherapeutic activity against numerous transplantable mouse and rat tumors.2 The initial Japanese reports of human trials of mitomycin C indicated that it had demonstrable chemotherapeutic activity against chronic myelogenous leukemia, chorioepithelioma, reticulum cell sarcoma, seminomas, and some epithelial tumors.3 Subsequent reports by American investigators using dosages similar to the Japanese investigators showed the drug to have limited value in leukemias and various sarcomas, but to have severe hematopoietic toxicity.4,5
This report presents our results using mitomycin C at a somewhat lower dosage schedule in 24 patients with advanced malignant disease arising from solid
Watne AL, Moore D, Gorgun B. Solid Tumor Chemotherapy With Mitomycin C. Arch Surg. 1967;95(2):175–178. doi:10.1001/archsurg.1967.01330140013003
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.